Figure Legends
Figure 1. Design of the microfluidic transfection device. (A) Photograph
of the serpentine device. (B) Schematic of microfluidic chaotic-based
delivery system used to transfect DNA into human myeloma cells. Briefly,
cells and DNA were mixed in suspension, chaotic advection creating
vortices in inner wall that disrupt cell membranes to permit
permeability and allow DNA to diffuse into cells. (C) simulation of
velocity magnitude (m/ s) in chip containing U-turn channels.
Figure 2. Microscopy of myeloma cells expressing green fluorescent
protein 24 hours post transfection in 2 different gene delivery systems:
(A) Non-transfected cell, (B) Nucleofection, (C) Microfluidic
Transfection Device.
Figure 3. Levels of EGFP protein expression in myeloma cells compared to
nucleofection. (A) Representative experiment for the percent of
transfected cells following microfluidic transfection reveals high GFP
expression and viability compared to nucleofection. (B) Transfection
efficiency in human myeloma cells transfected with various
concentrations of DNA via our microfluidic device.
Figure 4. Comparison of intracellular delivery methods in mRNA and
protein expression. (A) mRNA level measured by q RT-PCR of target gene
48h post transfection. The results are presented as the mean ± SD of
three different experiments, p<0.001. (B) Representative
percentage of myeloma cells that exhibit surface protein expression
after microfluidic processing and nucleofection 48 h post transfection.